224 related articles for article (PubMed ID: 35809794)
21. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
[TBL] [Abstract][Full Text] [Related]
22. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
23. Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma.
Bobillo S; Wilson MR; Cwynarski K
Curr Opin Oncol; 2023 Sep; 35(5):382-388. PubMed ID: 37551947
[TBL] [Abstract][Full Text] [Related]
24. Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?
Lantz J; Portell CA; Ayers EC
Blood Rev; 2023 Sep; 61():101101. PubMed ID: 37258362
[TBL] [Abstract][Full Text] [Related]
25. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
26. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
[TBL] [Abstract][Full Text] [Related]
27. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
28. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
Wilson MR; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Lees C; Fox C; Preston G; Ahearne M; Strüßmann T; Clavert A; Rusconi C; Ku M; Khwaja J; Narkhede M; Lewis K; Durot E; Smith J; Renaud L; Ferreri AJM; El-Galaly T; Cwynarski K; McKay P; Eyre TA
Am J Hematol; 2024 Feb; 99(2):E46-E50. PubMed ID: 38037530
[No Abstract] [Full Text] [Related]
29. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
31. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM; Ribera JM;
Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
[TBL] [Abstract][Full Text] [Related]
33. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.
Kuitunen H; Kaprio E; Karihtala P; Makkonen V; Kauppila S; Haapasaari KM; Kuusisto M; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
Ann Hematol; 2020 Aug; 99(8):1823-1831. PubMed ID: 32577843
[TBL] [Abstract][Full Text] [Related]
34. CNS prophylaxis in aggressive B-cell lymphoma.
Wilson MR; Bobillo S; Cwynarski K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):138-145. PubMed ID: 36485105
[TBL] [Abstract][Full Text] [Related]
35. Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL.
Terao T; Tsushima T; Ikeda D; Fukumoto A; Kamura Y; Kuzume A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
Leuk Lymphoma; 2022 Dec; 63(14):3394-3401. PubMed ID: 36111741
[TBL] [Abstract][Full Text] [Related]
36. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
37. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
Krmek DZ; Ljubić N; Vrbanić L
Acta Med Croatica; 2012 Dec; 66(5):403-7. PubMed ID: 23814970
[TBL] [Abstract][Full Text] [Related]
38. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
[TBL] [Abstract][Full Text] [Related]
39. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
40. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]